Evidence map›Paper›PMID 32210853›Full record

ArticleFrontiers in psychiatry2020

Crossing Death Valley: Bringing Neurotechnology to Psychiatric Clinics in Alberta, Canada.

Frank P MacMaster, Nick Mitchell, Allison Bichel, Marni Bercov, Gayle Thompson, Victoria Suen, Allison Strilchuk, Katherine Rittenbach

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Frank P MacMasterDepartment of Pediatrics and Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Nick MitchellStrategic Clinical Network for Addictions and Mental Health, Alberta Health Services, Calgary, AB, Canada.
Allison BichelStrategic Clinical Network for Addictions and Mental Health and Maternal, Newborn, Child & Youth Strategic Clinical Network, Alberta Health Services, Calgary, AB, Canada.
Marni BercovStrategic Clinical Network for Addictions and Mental Health, Alberta Health Services, Calgary, AB, Canada.
Gayle ThompsonStrategic Clinical Network for Addictions and Mental Health, Alberta Health Services, Calgary, AB, Canada.
Victoria SuenStrategic Clinical Network for Addictions and Mental Health, Alberta Health Services, Calgary, AB, Canada.
Allison StrilchukDepartment of Nephrology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Katherine RittenbachStrategic Clinical Network for Addictions and Mental Health, Alberta Health Services, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is a major public health problem, with a lifetime and 12-month prevalence estimated at 18 and 6% of adults. Depression is costly in terms of treatment and lost productivity and is the main burden of mental illness across the globe. Existing pharmacological and psychological treatments for depression result in clinically meaningful improvements in <60% of patients. An emerging treatment approach is non-invasive brain stimulation of depression-related brain targets through transcranial magnetic stimulation (TMS). In this perspective, we detail our efforts on bringing TMS to clinical populations in Alberta by utilizing a novel organizational structure that bridges the gap between academia and the health care system. The Addictions and Mental Health Strategic Clinical Network worked with stakeholders to (1) examine the evidence, (2) develop clinical tools for patient selection and protocol application, (3) create overall implementation and evaluation plans to aid in further scale and spread, and even (4) fund the purchase and deployment of devices. Through this work, five publicly supported clinics now exist in Alberta.

Indexed as

depressionhealth policyknowledge translationtranscranial magnetic stimulationtreatment resistant depression

Identifiers

PMID32210853
PMCPMC7067696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.